News

GATHER2 reports a 14.3% reduction in mean rate of growth in GA area over 12 months with avacincaptad pegol compared to sham.

The least squares mean change from baseline in BCVA at Week 8 was 6.7 letters for SB15 versus 6.6 letters for aflibercept.

The FDA granted a Priority Review to the leniolisib New Drug Application (NDA) indicated for individuals with activated phosphoinositide 3-kinase delta syndrome (APDS) 12 years and older.

A study finds delayed puberty, a comorbidity of epidermolysis bullosa, may affect skeletal health.

The FDA approved risankizumab for patients with Crohn's disease in June.

The research examined how anxiety and pre-bedtime behaviors that are often reported in primary care settings impact sleep health and discussed targeted interventions for effective treatment.

The FDA recently approved a drug treatment for prurigo nodularis, studied across over 60 clinical trials.

The investigators identified Osteoprotegerin in the serum of dupilumab treated patients, which could act as a predictor for clinical outcomes of dupilumab treatment.

A review examined the ways in which costs can be reduced for patients with varying types of atopic dermatitis.

Key opinion leaders in the cardiometabolic space describe the importance of the introduction of SGLT2 inhibitors for heart failure treatment based on 2022 guidelines.

The study explores the relationship between the ascending arousal network, its alterations, and its connections with cortical networks in chronic insomnia disorder.

The treatment resulted in significant improvements in the Eczema Area and Severity Index (EASI) scores and patient-reported outcome measure scores.

The majority of patients treated with systemic therapies were treated with dupilumab, while 3.2% patients received a combination of systemic therapies.

The investigators found minor differences in the microbial community structure between the control group and the chronic HCV group.

A majority of individuals who received one of the various cannabinoid products experienced a significant improvement in sleep quality and duration.

100 years after the discovery of insulin, the T1D Index may provide a foundational understanding of what steps need to be taken to both improve lives and reduce the incidence of T1D.

With the launch of the T1D index, the global burden of the disease and its impact is better understood. Dr. Kowalski joins to dig deeper into its importance and his personal connection to T1D.

Research suggests that tildrakizumab may be useful in real-life settings against moderate-to-severe plaque psoriasis.

In this regularly scheduled September 2022 episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide their own perspective on DIY looping based on the results of a recent study published in the New England Journal of Medicine and also break down a new set of consensus recommendations for the use of automated insulin delivery (AID) systems in clinical practice published in Endocrine Reviews, which Isaacs helped compose as a member of the writing committee.

PP-IRF through year 2 was independently associated with worse long-term visual acuity and scar development.

Patients with nAMD, DME, BRVO-ME, and CRVO-ME showed limited visual acuity outcomes in clinical practice.

NAFLD resulted in a number of other negative outcomes, including sleep disturbance, cardiovascular disease, significant hepatic fibrosis, and advanced hepatic fibrosis.

Conflicting evidence on the risks associated with intubation in patients with COVID-19 initiated a debate in the medical community regarding the benefit of utilizing high-flow oxygen.

A discussion was held regarding research on the use of antivirals on younger influenza patients.

The association between cumulative BMI and risk of NAFLD was more pronounced in women and younger participants.

Research has highlighted new information for the identification of risk factors for dementia.

Dr. Craig Granowitz of Lexicon Pharmaceuticals details the success of the LX9211 clinical trial for painful diabetic neuropathy and the unique study design.

Research finds potential benefits to using apremilast for plaque psoriasis patients.